Cargando…

1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model

BACKGROUND: ASN100 is a combination of two co-administered fully human monoclonal antibodies (mAbs), ASN-1 and ASN-2, that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis. ASN100 is in development for prevention of S. aureus pneumonia in mechanically ventilated pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubino, Christopher M, Stulik, Lukas, Rouha, Harald, Visram, Zehra, Badarau, Adriana, Wart, Scott A Van, Ambrose, Paul G, Goodwin, Matthew M, Nagy, Eszter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252729/
http://dx.doi.org/10.1093/ofid/ofy210.1219
_version_ 1783373330960613376
author Rubino, Christopher M
Stulik, Lukas
Rouha, Harald
Visram, Zehra
Badarau, Adriana
Wart, Scott A Van
Ambrose, Paul G
Goodwin, Matthew M
Nagy, Eszter
author_facet Rubino, Christopher M
Stulik, Lukas
Rouha, Harald
Visram, Zehra
Badarau, Adriana
Wart, Scott A Van
Ambrose, Paul G
Goodwin, Matthew M
Nagy, Eszter
author_sort Rubino, Christopher M
collection PubMed
description BACKGROUND: ASN100 is a combination of two co-administered fully human monoclonal antibodies (mAbs), ASN-1 and ASN-2, that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis. ASN100 is in development for prevention of S. aureus pneumonia in mechanically ventilated patients. A pharmacometric approach to dose discrimination in humans was taken in order to bridge from dose-ranging, survival studies in rabbits to anticipated human exposures using a mPBPK model derived from data from rabbits (infected and noninfected) and noninfected humans [IDWeek 2017, Poster 1849]. Survival in rabbits was assumed to be indicative of a protective effect through ASN100 neutralization of S. aureus toxins. METHODS: Data from studies in rabbits (placebo through 20 mg/kg single doses of ASN100, four strains representing MRSA and MSSA isolates with different toxin profiles) were pooled with data from a PK and efficacy study in infected rabbits (placebo and 40 mg/kg ASN100) [IDWeek 2017, Poster 1844]. A Cox proportional hazards model was used to relate survival to both strain and mAb exposure. Monte Carlo simulation was then applied to generate ASN100 exposures for simulated patients given a range of ASN100 doses and infection with each strain (n = 500 per scenario) using a mPBPK model. Using the Cox model, the probability of full protection from toxins (i.e., predicted survival) was estimated for each simulated patient. RESULTS: Cox models showed that survival in rabbits is dependent on both strain and ASN100 exposure in lung epithelial lining fluid (ELF). At human doses simulated (360–10,000 mg of ASN100), full or substantial protection is expected for all four strains tested. For the most virulent strain tested in the rabbit pneumonia study (a PVL-negative MSSA, Figure 1), the clinical dose of 3,600 mg of ASN100 provides substantially higher predicted effect relative to lower doses, while doses above 3,600 mg are not predicted to provide significant additional protection. CONCLUSION: A pharmacometric approach allowed for the translation of rabbit survival data to infected patients as well as discrimination of potential clinical doses. These results support the ASN100 dose of 3,600 mg currently being evaluated in a Phase 2 S. aureus pneumonia prevention trial. [Image: see text] DISCLOSURES: C. M. Rubino, Arsanis, Inc.: Research Contractor, Research support. L. Stulik, Arsanis Biosciences GmbH: Employee, Salary. H. Rouha, 3Arsanis Biosciences GmbH: Employee, Salary. Z. Visram, Arsanis Biosciences GmbH: Employee, Salary. A. Badarau, Arsanis Biosciences GmbH: Employee, Salary. S. A. Van Wart, Arsanis, Inc.: Research Contractor, Research support. P. G. Ambrose, Arsanis, Inc.: Research Contractor, Research support. M. M. Goodwin, Arsanis, Inc.: Employee, Salary. E. Nagy, Arsanis Biosciences GmbH: Employee, Salary.
format Online
Article
Text
id pubmed-6252729
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62527292018-11-28 1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model Rubino, Christopher M Stulik, Lukas Rouha, Harald Visram, Zehra Badarau, Adriana Wart, Scott A Van Ambrose, Paul G Goodwin, Matthew M Nagy, Eszter Open Forum Infect Dis Abstracts BACKGROUND: ASN100 is a combination of two co-administered fully human monoclonal antibodies (mAbs), ASN-1 and ASN-2, that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis. ASN100 is in development for prevention of S. aureus pneumonia in mechanically ventilated patients. A pharmacometric approach to dose discrimination in humans was taken in order to bridge from dose-ranging, survival studies in rabbits to anticipated human exposures using a mPBPK model derived from data from rabbits (infected and noninfected) and noninfected humans [IDWeek 2017, Poster 1849]. Survival in rabbits was assumed to be indicative of a protective effect through ASN100 neutralization of S. aureus toxins. METHODS: Data from studies in rabbits (placebo through 20 mg/kg single doses of ASN100, four strains representing MRSA and MSSA isolates with different toxin profiles) were pooled with data from a PK and efficacy study in infected rabbits (placebo and 40 mg/kg ASN100) [IDWeek 2017, Poster 1844]. A Cox proportional hazards model was used to relate survival to both strain and mAb exposure. Monte Carlo simulation was then applied to generate ASN100 exposures for simulated patients given a range of ASN100 doses and infection with each strain (n = 500 per scenario) using a mPBPK model. Using the Cox model, the probability of full protection from toxins (i.e., predicted survival) was estimated for each simulated patient. RESULTS: Cox models showed that survival in rabbits is dependent on both strain and ASN100 exposure in lung epithelial lining fluid (ELF). At human doses simulated (360–10,000 mg of ASN100), full or substantial protection is expected for all four strains tested. For the most virulent strain tested in the rabbit pneumonia study (a PVL-negative MSSA, Figure 1), the clinical dose of 3,600 mg of ASN100 provides substantially higher predicted effect relative to lower doses, while doses above 3,600 mg are not predicted to provide significant additional protection. CONCLUSION: A pharmacometric approach allowed for the translation of rabbit survival data to infected patients as well as discrimination of potential clinical doses. These results support the ASN100 dose of 3,600 mg currently being evaluated in a Phase 2 S. aureus pneumonia prevention trial. [Image: see text] DISCLOSURES: C. M. Rubino, Arsanis, Inc.: Research Contractor, Research support. L. Stulik, Arsanis Biosciences GmbH: Employee, Salary. H. Rouha, 3Arsanis Biosciences GmbH: Employee, Salary. Z. Visram, Arsanis Biosciences GmbH: Employee, Salary. A. Badarau, Arsanis Biosciences GmbH: Employee, Salary. S. A. Van Wart, Arsanis, Inc.: Research Contractor, Research support. P. G. Ambrose, Arsanis, Inc.: Research Contractor, Research support. M. M. Goodwin, Arsanis, Inc.: Employee, Salary. E. Nagy, Arsanis Biosciences GmbH: Employee, Salary. Oxford University Press 2018-11-26 /pmc/articles/PMC6252729/ http://dx.doi.org/10.1093/ofid/ofy210.1219 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Rubino, Christopher M
Stulik, Lukas
Rouha, Harald
Visram, Zehra
Badarau, Adriana
Wart, Scott A Van
Ambrose, Paul G
Goodwin, Matthew M
Nagy, Eszter
1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model
title 1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model
title_full 1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model
title_fullStr 1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model
title_full_unstemmed 1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model
title_short 1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model
title_sort 1388. dose discrimination for asn100: bridging from rabbit survival data to predicted activity in humans using a minimal physiologically based pharmacokinetic (mpbpk) model
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252729/
http://dx.doi.org/10.1093/ofid/ofy210.1219
work_keys_str_mv AT rubinochristopherm 1388dosediscriminationforasn100bridgingfromrabbitsurvivaldatatopredictedactivityinhumansusingaminimalphysiologicallybasedpharmacokineticmpbpkmodel
AT stuliklukas 1388dosediscriminationforasn100bridgingfromrabbitsurvivaldatatopredictedactivityinhumansusingaminimalphysiologicallybasedpharmacokineticmpbpkmodel
AT rouhaharald 1388dosediscriminationforasn100bridgingfromrabbitsurvivaldatatopredictedactivityinhumansusingaminimalphysiologicallybasedpharmacokineticmpbpkmodel
AT visramzehra 1388dosediscriminationforasn100bridgingfromrabbitsurvivaldatatopredictedactivityinhumansusingaminimalphysiologicallybasedpharmacokineticmpbpkmodel
AT badarauadriana 1388dosediscriminationforasn100bridgingfromrabbitsurvivaldatatopredictedactivityinhumansusingaminimalphysiologicallybasedpharmacokineticmpbpkmodel
AT wartscottavan 1388dosediscriminationforasn100bridgingfromrabbitsurvivaldatatopredictedactivityinhumansusingaminimalphysiologicallybasedpharmacokineticmpbpkmodel
AT ambrosepaulg 1388dosediscriminationforasn100bridgingfromrabbitsurvivaldatatopredictedactivityinhumansusingaminimalphysiologicallybasedpharmacokineticmpbpkmodel
AT goodwinmatthewm 1388dosediscriminationforasn100bridgingfromrabbitsurvivaldatatopredictedactivityinhumansusingaminimalphysiologicallybasedpharmacokineticmpbpkmodel
AT nagyeszter 1388dosediscriminationforasn100bridgingfromrabbitsurvivaldatatopredictedactivityinhumansusingaminimalphysiologicallybasedpharmacokineticmpbpkmodel